¹⁸F-FDG PET/CT-based treatment response evaluation in locally advanced rectal cancer: a prospective validation of long-term outcomes.
about
Role of PET quantitation in the monitoring of cancer response to treatment: Review of approaches and human clinical trials.Assessment of response to neoadjuvant radiochemotherapy with F-18 FLT and F-18 FDG PET/CT in patients with rectal cancer.Positron emission tomography/computed tomography and biomarkers for early treatment response evaluation in metastatic colon cancer.Systematic review of FDG-PET prediction of complete pathological response and survival in rectal cancer.Radiotherapy response evaluation using FDG PET-CT-established and emerging applications.The predictive value of 18F-FDG PET/CT for assessing pathological response and survival in locally advanced rectal cancer after neoadjuvant radiochemotherapy.Human cytomegalovirus and Epstein-Barr virus infection impact on (18)F-FDG PET/CT SUVmax, CT volumetric and KRAS-based parameters of patients with locally advanced rectal cancer treated with neoadjuvant therapy.Metabolic and molecular relative percentage coreduction in patients with locally advanced rectal cancer treated with neoadjuvant therapy.The emerging role of FDG PET/CT in rectal cancer management: is it time to use the technique for early prognostication?18F-FDG PET predicts pathological response to preoperative chemoradiotherapy in patients with primary rectal cancer: a meta-analysis.Clinical significance of VEGFR-2 and ¹⁸F-FDG PET/CT SUVmax pretreatment score in predicting the long-term outcome of patients with locally advanced rectal cancer treated with neoadjuvant therapy.Is diffusion-weighted MRI superior to FDG-PET or FDG-PET/CT in evaluating and predicting pathological response to preoperative neoadjuvant therapy in patients with rectal cancer?[Importance of FDG-PET/CT for surgery of rectal cancer].
P2860
Q34175770-265BD021-CCB3-472E-B8C4-8B6C4DCAF943Q36322912-2273DA18-80A5-485B-BD97-733E5A551D8DQ37589065-FEE58CEF-98EB-4879-ABAD-CFB8BDFC6F1EQ38209862-5FD02335-CD87-42DE-A231-EE4BF91A983DQ39051286-1D8484F7-CD07-4F20-8ABF-529BF7A8E344Q41425861-A0872D85-4264-46A0-90BF-F9A13C45C105Q41721184-A764D471-E6E6-4AB7-9775-0514B82A7C5FQ43345082-4C52D9F4-81D9-406A-8136-BC21568570D1Q45899555-8F393E97-9959-46D2-9F02-F8C3E7A13F25Q45920677-B386AFB7-1A8D-479A-94EF-E44286BD6BD2Q50878258-F6F9796D-4DD5-4381-854E-107924B7C4B2Q53058913-2726D0DF-61F2-4F18-8231-556143948A5DQ53073433-27C934BF-4B55-485F-9E5E-9E91307F0AB6
P2860
¹⁸F-FDG PET/CT-based treatment response evaluation in locally advanced rectal cancer: a prospective validation of long-term outcomes.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
¹⁸F-FDG PET/CT-based treatment ...... idation of long-term outcomes.
@en
¹⁸F-FDG PET/CT-based treatment ...... idation of long-term outcomes.
@nl
type
label
¹⁸F-FDG PET/CT-based treatment ...... idation of long-term outcomes.
@en
¹⁸F-FDG PET/CT-based treatment ...... idation of long-term outcomes.
@nl
prefLabel
¹⁸F-FDG PET/CT-based treatment ...... idation of long-term outcomes.
@en
¹⁸F-FDG PET/CT-based treatment ...... idation of long-term outcomes.
@nl
P2093
P2860
P1476
¹⁸F-FDG PET/CT-based treatment ...... idation of long-term outcomes.
@en
P2093
Dolores de la Mata
Emilio Alvarez
Felipe A Calvo
José L Carreras
Luis Cabezón
Marina Gómez-Espí
Paz Madariaga
P2860
P2888
P304
P356
10.1007/S00259-013-2341-Y
P577
2013-02-23T00:00:00Z